Is NCT06659549 recruiting in Beverly Hills, CA?

Yes, NCT06659549 is currently recruiting participants at its Beverly Hills, CA location. This macular degeneration clinical trial is actively enrolling qualified participants.

How do I join the macular degeneration clinical trial in Beverly Hills?

To join this clinical trial in Beverly Hills, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Beverly Hills clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Macular Degeneration Clinical Trial in Beverly Hills, CA

About This Macular Degeneration Study in Beverly Hills

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and detai

Sponsor: Galimedix Therapeutics Inc

Who Can Participate

Inclusion Criteria

≥55 years of age

Willing and able to provide written informed consent

Willing and able to comply with the study schedule and study assessments

Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution

BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline

Refractive error between +3 and -6 diopters spherical equivalent in the study eye

Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline

Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center

Well-delineated cumulative GA area between 1.25 and 12.0 mm2

If GA is multifocal, at least 1 lesion ≥1.25 mm2

GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium \[RPE\] and outer retina)

GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea

GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be \>300 µm from image edges

GA lesions must be \>300 µm from the optic disc and/or peripapillary atrophy

Area of PRD must be cumulatively between 7.25 and 25.0 mm2

Exclusion Criteria

Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline

History of laser therapy in the macular region, regardless of indication

History of herpes zoster

Ophthalmic disease or condition that requires or is likely to require surgery during the study period

GA with cumulative area \<1.25 mm2

Any GA lesion within 100 µm radius from the center point of the fovea

Axial length \>26 mm

Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)

Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period

Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period

Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period

Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period Non-study Eye:

BCVA of \<5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent) Either Eye:

History of uveitis

GA secondary to any condition other than non-neovascular AMD

History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline

Underwent investigational treatment for AMD within 6 months before Visit 1a General Exclusion Criteria:

History of therapeutic radiation to the cranium

Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients

History of malignant disease

Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period

Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period

Use of lutein \>10 mg per day or zeaxanthin \>2 mg per day within 1 month before Visit 1a, or planned use during the study period

Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data

Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation

Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline

Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Beverly Hills?

Yes, this clinical trial (NCT06659549) has an active research site in Beverly Hills, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Macular Degeneration Treatment Options in Beverly Hills, CA

If you're searching for macular degeneration treatment options in Beverly Hills, CA, this clinical trial (NCT06659549) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Beverly Hills research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all macular degeneration clinical trials near you to find additional studies recruiting in your area.

Macular Degeneration Clinical Trial in Beverly Hills, CA

Expert Care in Beverly Hills

IRB Approved

No-Cost Care

Apply for This Beverly Hills Location

Why Participate?

Simple Process